A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
- Status
- TERMINATED
- Phase
- PHASE3
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and High-dose Melphalan at Myeloma Relapse
- Status
- UNKNOWN
- Phase
- PHASE2
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2